These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21503919)

  • 1. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
    Azakami T; Hayes CN; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Nakamura Y; Kamatani N; Chayama K
    J Med Virol; 2011 Jun; 83(6):1048-57. PubMed ID: 21503919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
    Ahmed WH; Furusyo N; Zaky S; Eldin AS; Aboalam H; Ogawa E; Murata M; Hayashi J
    World J Gastroenterol; 2013 Mar; 19(9):1387-95. PubMed ID: 23538996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
    Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
    BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
    Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
    Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
    Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
    Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
    Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Makokha GN; Ochi H; Amano H; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Gastroenterol; 2017 Jun; 52(6):746-753. PubMed ID: 27822709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Matsuura K; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Tokunaga K; Mizokami M; Izumi N
    J Med Virol; 2013 Mar; 85(3):449-58. PubMed ID: 23297176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
    Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
    J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
    Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
    Domingo P; Guardiola JM; Salazar J; Torres F; Mateo MG; Pacho C; Del Mar Gutierrez M; Lamarca K; Fontanet A; Martin J; Muñoz J; Vidal F; Baiget M
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2987-93. PubMed ID: 22430973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.
    Akamatsu S; Hayes CN; Tsuge M; Murakami E; Hiraga N; Abe H; Miki D; Imamura M; Ochi H; Chayama K;
    J Viral Hepat; 2015 Feb; 22(2):166-74. PubMed ID: 24930407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Kozuka R; Hai H; Teranishi Y; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1495-1502. PubMed ID: 28109022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.